| Entry |
|
|---|
| Name |
Linagliptin (JAN/USAN/INN);
Tradjenta (TN)
|
|---|
| Product |
|
|---|
| Formula |
C25H28N8O2
|
|---|
| Exact mass |
472.2335
|
|---|
| Mol weight |
472.5422
|
|---|
| Structure |
   |
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 3969 |
| Product (mixture): | D10264<US> D10588<JP/US> |
|
|---|
| Efficacy |
Antidiabetic, Dipeptidyl peptidase-4 (DPP-4) inhibitor |
|---|
| Disease |
Type 2 diabetes mellitus [DS: H00409] |
|---|
| Comment |
Treatment of type 2 diabetes
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04974 | Protein digestion and absorption |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH05 Linagliptin
D09566 Linagliptin (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Linagliptin
D09566 Linagliptin (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D09566 Linagliptin (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Peptidyl-peptidases
DPP4 (CD26)
D09566 Linagliptin (JAN/USAN/INN) <JP/US>
Drug classes of therapeutic agents [br08360.html]
Antidiabetic agents
D09566
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D09566
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09566
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09566
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09566
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 35
1 C8x C 15.6073 -25.1957
2 C8x C 15.6073 -26.5954
3 C8x C 16.7971 -27.2953
4 C8y C 18.1269 -26.5954
5 C8y C 18.1269 -25.1957
6 C8x C 16.7971 -24.4958
7 C8y C 19.3167 -27.2953
8 N5x N 20.5065 -26.5954
9 C8y C 20.5065 -25.1957
10 N5x N 19.3167 -24.4958
11 C1a C 19.3167 -28.6950
12 C1b C 21.6963 -24.4958
13 N4y N 22.8860 -25.1957
14 C8y C 22.8860 -26.5954
15 N4y N 24.1458 -27.2953
16 C8y C 25.3356 -26.5954
17 C8y C 25.3356 -25.1957
18 C8y C 24.1458 -24.4958
19 O5x O 24.1458 -23.0960
20 O5x O 21.6963 -27.2953
21 C1a C 24.1458 -28.6950
22 N5x N 26.6654 -27.0153
23 C8y C 27.5053 -25.8955
24 N4y N 26.6654 -24.7757
25 N1y N 28.9050 -25.8955
26 C1x C 29.6049 -27.0853
27 C1y C 31.0046 -27.0853
28 C1x C 31.7045 -25.8955
29 C1x C 31.0046 -24.7057
30 C1x C 29.6049 -24.7057
31 N1a N 31.7045 -28.3451
32 C1b C 27.3653 -23.5859
33 C3b C 28.7650 -23.5859
34 C3b C 30.1648 -23.5859
35 C1a C 31.5646 -23.5859
BOND 39
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 2
7 4 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 5 10 1
12 7 11 1
13 9 12 1
14 12 13 1
15 13 14 1
16 14 15 1
17 15 16 1
18 16 17 2
19 17 18 1
20 13 18 1
21 18 19 2
22 14 20 2
23 15 21 1
24 16 22 1
25 22 23 2
26 23 24 1
27 17 24 1
28 23 25 1
29 25 26 1
30 26 27 1
31 27 28 1
32 28 29 1
33 29 30 1
34 25 30 1
35 27 31 1 #Up
36 32 33 1
37 32 24 1
38 33 34 3
39 34 35 1
|
|---|
